Eterna Therapeutics announced positive preclinical results for its lead cell therapy product, ERNA-101, in treating ovarian cancer. The study...

Quoin Pharmaceuticals (QNRX) announced positive interim data from its ongoing pediatric Netherton Syndrome clinical study of QRX003, a topical...

Pasithea Therapeutics, a clinical-stage biotechnology company, has expanded its Phase 1 clinical trial of PAS-004, a next-generation MEK inhibitor,...

AskBio, a Bayer subsidiary, has initiated a Phase II clinical trial, REGENERATE-PD, for its Parkinson’s disease gene therapy, AB-1005...

HMNC Brain Health has completed patient randomization for its Phase 2b OLIVE trial, investigating the efficacy and safety of...

Totus Medicines initiated an expansion study for TOS-358, a first-in-class covalent PI3Kα inhibitor, after a successful Phase 1 trial....

Immunis, Inc., a clinical-stage biotech company, secured $25 million in Series A-1 funding to advance two Phase 2 clinical...

Sage Therapeutics announced its 2025 strategic focus, centering on the growth of ZURZUVAE (zuranolone) for postpartum depression (PPD) and...

Synchron, a brain-computer interface (BCI) company, is partnering with NVIDIA to enhance its implantable BCI technology using the NVIDIA...

Ashvattha Therapeutics secured up to $50 million in extended Series B funding, led by Tribe Capital and existing investors...